Clinical Activity Following the Administration of the MAGE-A3 Antigen-specific Cancer Immunotherapeutic in Both the Melanoma and NSCLC is Associated With Similar Predictive Biomarkers Present Prior Treatment

Lehmann, F; Ulloa-Montoya, F; Gruselle, O; Dizier, B; Louahed, Jamila; Vansteenkiste, Johan; Spatz, A; Kruit, W; Brichard, V

Journal of Immunotherapy

Clinical Activity Following the Administration of the MAGE-A3 Antigen-specific Cancer Immunotherapeutic in Both the Melanoma and NSCLC is Associated With Similar Predictive Biomarkers Present Prior Treatment

Author:

Lehmann, F

Ulloa-Montoya, F ; Gruselle, O ; Dizier, B ; Louahed, Jamila ; Vansteenkiste, Johan ; Spatz, A ; Kruit, W ; Brichard, V

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, Immunology, Medicine, Research & Experimental, Research & Experimental Medicine, 1107 Immunology, 3204 Immunology, 3211 Oncology and carcinogenesis

Journal of Immunotherapy Clinical Activity Following the Administration of the MAGE-A3 Antigen-specific Cancer Immunotherapeutic in Both the Melanoma and NSCLC is Associated With Similar Predictive Biomarkers Present Prior Treatment

Author:

Keywords:

Journal of Immunotherapy

Clinical Activity Following the Administration of the MAGE-A3 Antigen-specific Cancer Immunotherapeutic in Both the Melanoma and NSCLC is Associated With Similar Predictive Biomarkers Present Prior Treatment